Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Probiotic pill shows promise for fewer sniffles in healthy aussies

NCT ID NCT06837961

Symptom relief Sponsor: RDC Clinical Pty Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a daily probiotic tablet (LC-Plasma) could boost the immune system and reduce cold symptoms in healthy adults. 241 Australian volunteers took either the probiotic or a placebo for 4 weeks. Researchers measured immune cell activity and tracked any upper respiratory infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

241 people

The number who actually took part.

Started

Apr 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals who can provide a signed and dated informed consent form after confirming their willingness to participate. * Individuals willing to comply with all study procedures during the study period, including daily monitoring record compliance, cooperating with blood and urine sample collection and performing regular RATs. * Healthy people living in Australia aged 18-60 (both men and women). * Individuals who have received at least two doses of a SARS-CoV-2 vaccine, with at least two weeks having passed since the last dose. * Individuals who are not currently infected with SARS-CoV-2 and, if previously infected, have recovered and have been infection-free for at least four weeks. * Individuals who do not have any chronic or acute illnesses, including respiratory and/or gastrointestinal and/or other diseases, (e.g. hypertension, IBS, IBD, SLE, cancer, asthma, primary or secondary immunodeficiencies etc.), at the time of enrolment. Exclusion Criteria: * Individuals medically prescribed medications that would affect the immune and/or the inflammatory response. * Individuals deemed unsuitable for participation by Griffith CTU staff and/or the study clinician. * Active smokers/vapers and/or individuals with nicotine or drug habits. * Individuals currently participating in (or planning to participate in) other clinical trials. * Women who are pregnant, planning to become pregnant during the study period, or are currently breastfeeding. * Individuals unable to abstain from alcohol for two days prior to blood and urine sample collection. * Individuals unable to refrain from consuming other lactic acid bacteria supplements. * Individuals who are known to be HIV, HTLV-1, or HCV positive (based on answers to the enrolment questionnaire).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy volunteer Immune response

Contacts and locations

Locations

  • Griffith University

    Southport, Queensland, 4215, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.